During the past trading week (December 30 to January 3), Illinois kicked off the new year with the first legal sales of recreational cannabis, raking in millions on the first day.

A cannabis firm confirmed that its takeover deal with a major US-based multi-state operator (MSO) is in the final stretches, and a player in the Canadian marijuana space filed updated audited financial statements following a series of missteps at the company.


Here’s a closer look at some of the biggest cannabis news over the week.

Illinois makes millions on first day of legal cannabis

Cannabis consumers in Illinois got the chance to start 2020 off with the first purchases of legal recreational marijuana in the state when legalization went into effect on Wednesday (January 1).

There were over 77,000 transactions for the first day with nearly US$3.2 million in sales, said Toi Hutchinson, Illinois Governor J. B. Pritzker’s senior advisor for cannabis control, during a press conference on Thursday (January 2).

The first sale in the state took place at one of Cresco Labs’ (CSE:CL,OTCQX:CRLBF) dispensaries, according to the Illinois-based MSO, once retail locations opened on the morning of new year’s day.

The firm said it served over 3,000 people on Wednesday though its five retail stores, with an average ticket price of US$135.

Charlie Bachtell, Cresco Labs’ CEO, said in a statement that the new era of cannabis legalization will help bring about social equity and will create new ownership opportunities across the state.

“With 13 million residents and 100 million annual tourists, Illinois is predicted to be one of the largest recreational cannabis markets in the United States,” Bachtell said.

Illinois’ large addressable market and robust tourism industry have been said to be major drivers of growth for cannabis in the state. A report from research firm Brightfield Group states that Illinois’ marijuana market could rival that of Colorado once it gets going in earnest, and Marijuana Business Daily estimates the state could generate up to US$2.5 billion a year from cannabis sales.

Fellow Illinois native Green Thumb Industries (GTI) (CSE:GTII,OTCQX:GTBIF) also provided investors with an overview of its first day in the recreational cannabis market.

In a statement, GTI CEO Ben Kovler said the company’s line of stores in Illinois served thousands of people, and that the firm opened the first adult-use-only store in Illinois.

Illinois took its first step in adult-use cannabis legalization back in June, when Pritzker signed the Cannabis Regulation and Tax Act.

It was implemented “in the interest of allowing law enforcement to focus on violent and property crimes, generating revenue for education, substance abuse prevention and treatment, freeing public resources to invest in communities and other public purposes, and individual freedom.”

In a historic move, Illinois became the first state to legalize adult use of the drug through its legislature instead of via a citizen-led initiative.

Legalization comes after Pritzker announced on Tuesday (December 31) that over 11,000 low-level marijuana charges were pardoned in the first wave of expungements as a part of the new cannabis law.

Origin House, HEXO make significant moves over holidays

Two cannabis players took the slow period over the holidays to tell investors about critical movements.

Origin House (CSE:OH,OTCQX:ORHOF) confirmed on Tuesday that over 99 percent of its shareholders have voted in favor of its acquisition by Cresco Labs.

“Today, our shareholders have demonstrated that they are solidly behind our proposed arrangement with Cresco Labs,” said CEO Marc Lustig in a statement.

The news comes after the MSO revealed that the deal, first announced in April, would be reduced through a non-brokered financing on the part of Origin House. The transaction is expected to close soon after the firm files an order for approval with the Ontario Superior Court of Justice on January 6.

For its part, HEXO (NYSE:HEXO,TSX:HEXO) walked back financial statements for its fiscal 2019 year after discovering that a deferred tax liability went unaccounted for.

The company said its deferred tax liability was overstated by C$14.3 million after realizing a tax asset from one of its subsidiaries wasn’t considered against a deferred tax liability from a separate subsidiary.

HEXO said it first believed the two tax positions couldn’t be used to offset each other since they were generated in separate entities.

With the error adjusted, the company said its new net loss for the fiscal 2019 year is C$69.6 million, down from the C$81.6 million originally reported.

Market updates

On Thursday, Tilray (NASDAQ:TLRY) took steps to establish itself in the Middle East with a strategic agreement with Canndoc, a subsidiary of Israel-based InterCure (TLV:INCR). Through its own subsidiary, Tilray Portugal Unipessoal, Tilray plans to export 2.5 tons of medical cannabis to Israel from Portugal this month, becoming the first cannabis company to do so.

“To be able to import medical cannabis into Israel for patients in need is truly a historic moment not only for Tilray, but the whole industry,” said Brendan Kennedy, Tilray’s CEO, in a statement.

As of Wednesday, people in Quebec under the age of 21 won’t be able to purchase recreational cannabis, creating some of the most strict cannabis laws in the country. Other provinces in Canada have an age limit set at 18 or 19 years of age to buy and use the drug.

The news comes after Quebec banned edible cannabis-infused products in July in the hopes of preventing cannabis use by children.

At the time, the Quebec Cannabis Industry Association called the move “a shot across the bow for all Quebec businesses,” as it raised concerns for cannabis companies about the sale of edible products in the province.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less